Advertisement

Topics

Latest "Debiopharm Group" News Stories

00:09 EDT 17th July 2018 | BioPortfolio

Here are the most relevant search results for "Debiopharm Group" found in our extensive news archives from over 250 global news sources.

More Information about Debiopharm Group on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Debiopharm Group for you to read. Along with our medical data and news we also list Debiopharm Group Clinical Trials, which are updated daily. BioPortfolio also has a large database of Debiopharm Group Companies for you to search.

Showing "Debiopharm Group" News Articles 1–25 of 9,700+

Extremely Relevant

Debiopharm continues fight against antibiotic resistance

Debiopharm Group invests in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics


Debiopharm poursuit le combat contre les résistances aux antibiotiques avec un investissement ...

Debiopharm Group™ annonce un investissement dans les antibiotiques avec l'acquisition d'une part minoritaire de la société ABAC Therapeutics Inc. Cette prise de participation par le Read more...

Relevant

Series A lands €16mm for ABAC Therapeutics

Antibiotics developer ABAC Therapeutics raised €16mm ($19.8mm) in its Series A financing led by Pontifax, which was joined ...


Biopharm group continues efforts in fight against antibiotic resistance through investment

Debiopharm Group, international biopharmaceutical group, has continued its efforts in the fight against antibiotic resistance by investing in antibiotic development through acquiring a minority stake in ABAC Therapeutics.

Debiopharm Strengthens Compliance, Clinical Trial Oversight With Veeva Vault eTMF

Clinical Informatics News Brief | Veeva Systems announced that Debiopharm selected Veeva Vault eTMF to improve oversight across its trial master file processes and work closely with contract research organizations by collaborating on a single, cloud-based application.    

ABAC Therapeutics raises 16 million euros from investors including Debiopharm

Spain-based ABAC Therapeutics, a leader in pathogen-specific antibiotics, announced today the closing…

Debiopharm International SA Strengthens Compliance and Clinical Trial Oversight with Veeva Vault eTMF

Global biopharmaceutical company enables real-time inspection readiness and improves CRO collaboration Veeva Systems (NYSE: VEEV) announced today that

Debiopharm Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryDebiopharm Group Debiopharm is a pharmaceutical company that develops biologics and small molecule drug candidates targeted at unmet medical needs. The company provides products portfolio such as eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also provides services such as clinical development, manufacturing and qua...

PTV News: Jan 8, 2010

Top stories on January 8th, 2010: Huge potential: Vivus obesity drug cuts sleep apnea too Lundbeck investigated by EU over generic claims Second stab: Debiopharm to develop Pfizer failure Cyclacel's changing fortunes Action Shares Risk averse: Why Australian investors are still shy of biotech

Debiopharm Innovation Fund SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryDebiopharm Innovation Fund SA Debiopharm Diagnostics, formerly Debiopharm Diagnostics SA, a subsidiary of Debiopharm Group, is a patient care investment company that offers drug investments and development stage diagnostics solutions. The company offers investments for drugs on cancer severity and recurrence, omics and clinical big data management, point of care turnkey Dx platforms, bloodb...

Debiopharm International SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and inlicenses promising drug candidates for development. Debiopharm's products includes decapeptyl, eloxatin, pamorelin, trelstar, moapar and salvacyl among o...

Probably Relevant

Unlimited Group appoints group managing director

Michael Richards joins the group from VCCP

TMX Group Limited Declares Dividend of $0.50 per Common Share

For the results of the quarter ended December 31, 2017for TMX Group, please click on the following link: http://www.tmx.com/investor-relations/ About TMX Group (TSX:X) TMX Read more...

North 6th Agency Announces N6-Accolades For March 2018

The N6A Cybersecurity & Digital Identity Group took home the "N6A Golden Group" trophy as the highest-performing group for the month. At the end of Read more...

New haematology patient group launched

The launch of a new patient engagement group for those with blood conditions has brought together patients, clinicians and researchers to discuss how to get patient involved in research. A screening of the film People are Messy at the Ultimate Picture Palace followed by a group discussion marked the launch of the Oxford Blood Group, a new local ... Read more

Group 1 Automotive Appoints UK Operating Leader

HOUSTON, Feb. 28, 2018/PRNewswire/ --  Group 1 Automotive, Inc. (NYSE: GPI), ("Group 1" or the "Company"), an international, Fortune 500 automotive retailer, Read more...

The Stars Group anuncia la oferta privada de 1. ...

The Stars Group Inc. (NASDAQ: TSG) (TSX: TSGI) ('The Stars Group' o 'la compañía') anunció hoy el aumento de tamaño y precio por medio Read more...

Group 1 Automotive Acquires Two Additional Dealerships in El Paso, Texas

HOUSTON, Jan. 29, 2018/PRNewswire/ --  Group 1 Automotive, Inc. (NYSE: GPI), ("Group 1" or the "Company"), an international, Fortune 500 automotive Read more...

Group medical visits fail to improve outcomes in patients with diabetes

Group medical visits — the combination of group self-management education and one-on-one consultations with clinicians — did not improve several medical outcomes in patients with diabetes, according to findings recently published in the Journal of the American Board of Family Medicine.“While diabetes group visits have been evaluated before, most evaluations have been pilots or randomized-con...

EDB Group: Carola Schropp on the Role of EBD Group conferences in partnering and deal making

In this episode of PharmaTelevsion News Review, Fintan Walton discusses the recent BioPharm America conference in Boston with Carola Schropp from the EBD Group. • Role of EBD Group conferences in partnering and deal making • The impact of conferences in actual deal making • EBD Group 's perspective: The state and changes in pharma and biotech industry • EBD Group 's perspective on futu...

Therap Responds to Newly Released Joint OIG, ACL, and OCR Incident Management Report in Group Homes

Group homes reported all critical incidents; All critical incidents reported by group homes were properly recorded; Group homes reported incidents at the correct severity level; Read more...

Die Stars Group kündigt Preis für Public Offering von Stammaktien an

Die Stars Group Inc. (Nasdaq: TSG) (TSX: TSGI) ("die Stars Group" oder "die Gesellschaft") gab heute das Upsizing und Pricing für sein unterzeichnetes Proposed Public Read more...

Group 1 Automotive to Present at the Bank of America Merrill Lynch 2018 Auto Summit in New York City

HOUSTON, March 26, 2018/PRNewswire/ --  Group 1 Automotive, Inc.(NYSE: GPI), ("Group 1" or the "Company"), an international, Fortune 500 automotive Read more...

Sugal Damani y The Stars Group anuncian el lanzamiento de Pokerstars.IN en abril

CALCUTA, la Indiay TORONTO, 28 de marzo de 2018 /PRNewswire/ -- Sugal & Damani Group y The Stars Group Inc. anunciaron hoy que Read more...

Sugal Damani e The Stars Group anunciam o lançamento em abril do Pokerstars.IN

CALCUTÁ, Índia e TORONTO, 28 de março de 2018 /PRNewswire/ -- O Sugal & Damani Group e o The Stars Group Inc. anunciaram hoje Read more...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks